Predicting cisplatin ototoxicity in children: the influence of age and the cumulative dose - PubMed (original) (raw)
Predicting cisplatin ototoxicity in children: the influence of age and the cumulative dose
Y Li et al. Eur J Cancer. 2004 Nov.
Abstract
The aim of this study was to determine the risk factors for high-frequency hearing loss in children treated with cisplatin. We scored off-treatment pure-tone audiograms from 153 children (age 6 months to 18 years) who had completed cisplatin therapy (40-200 mg/m(2)/cycle) for germ cell tumours, hepatoblastoma, neuroblastoma or osteosarcoma. The risk of developing bilateral moderate to severe high-frequency hearing loss was significantly related to the age at treatment (P<0.001), and individual and cumulative cisplatin dosages (both P<0.005). Logistic regression showed that children younger than 5 years were at a greater risk of sustaining cisplatin ototoxicity than children older than 15 years, controlling for individual and cumulative doses of cisplatin (Odds Ratio (OR)=21.17, 95% Confidence Interval (CI): 2.48-180.94). Age at treatment and the cumulative dose of cisplatin were the two most important risk factors in predicting moderate to severe high-frequency hearing loss in children treated with cisplatin.
Comment in
- Best practice in assessing ototoxicity in children with cancer.
Skinner R. Skinner R. Eur J Cancer. 2004 Nov;40(16):2352-4. doi: 10.1016/j.ejca.2004.08.002. Eur J Cancer. 2004. PMID: 15519505 No abstract available.
Similar articles
- Platinum compound-related ototoxicity in children: long-term follow-up reveals continuous worsening of hearing loss.
Bertolini P, Lassalle M, Mercier G, Raquin MA, Izzi G, Corradini N, Hartmann O. Bertolini P, et al. J Pediatr Hematol Oncol. 2004 Oct;26(10):649-55. J Pediatr Hematol Oncol. 2004. PMID: 15454836 - Ototoxicity in children treated for osteosarcoma.
Lewis MJ, DuBois SG, Fligor B, Li X, Goorin A, Grier HE. Lewis MJ, et al. Pediatr Blood Cancer. 2009 Mar;52(3):387-91. doi: 10.1002/pbc.21875. Pediatr Blood Cancer. 2009. PMID: 19061216 - [Ototoxicity of cisplatin in children with malignant diseases].
Hadjilaskari P, Fengler R, Hartmann R, Henze G. Hadjilaskari P, et al. Klin Padiatr. 1989 Jul-Aug;201(4):316-21. doi: 10.1055/s-2008-1026721. Klin Padiatr. 1989. PMID: 2779137 German. - Practical grading system for evaluating cisplatin ototoxicity in children.
Chang KW, Chinosornvatana N. Chang KW, et al. J Clin Oncol. 2010 Apr 1;28(10):1788-95. doi: 10.1200/JCO.2009.24.4228. Epub 2010 Mar 1. J Clin Oncol. 2010. PMID: 20194861 Review. - Assessment of hearing in very young children receiving carboplatin for retinoblastoma.
Smits C, Swen SJ, Theo Goverts S, Moll AC, Imhof SM, Schouten-van Meeteren AY. Smits C, et al. Eur J Cancer. 2006 Mar;42(4):492-500. doi: 10.1016/j.ejca.2005.11.004. Epub 2006 Jan 11. Eur J Cancer. 2006. PMID: 16376542 Review.
Cited by
- Long-term quality of survival after pediatric low-grade glioma.
de Bont JM, Schouten-van Meeteren AYN. de Bont JM, et al. Childs Nerv Syst. 2024 Oct;40(10):3341-3355. doi: 10.1007/s00381-024-06631-1. Epub 2024 Oct 14. Childs Nerv Syst. 2024. PMID: 39400717 Review. - Leveraging large-scale datasets and single cell omics data to develop a polygenic score for cisplatin-induced ototoxicity.
Miao DNR, Wilke MAP, Pham J, Ladha F, Singh M, Arsenio J, Luca E, Dabdoub A, Yang W, Yang JJ, Drögemöller BI. Miao DNR, et al. Hum Genomics. 2024 Oct 8;18(1):112. doi: 10.1186/s40246-024-00679-5. Hum Genomics. 2024. PMID: 39380081 Free PMC article. - Modulating the unfolded protein response with ISRIB mitigates cisplatin ototoxicity.
Li J, Rouse SL, Matthews IR, Park Y, Eltawil Y, Sherr EH, Chan DK. Li J, et al. Sci Rep. 2024 Sep 27;14(1):22382. doi: 10.1038/s41598-024-70561-w. Sci Rep. 2024. PMID: 39333235 Free PMC article. - Inhibition of the HMGB1/RAGE axis protects against cisplatin-induced ototoxicity via suppression of inflammation and oxidative stress.
Qiao X, Li W, Zheng Z, Liu C, Zhao L, He Y, Li H. Qiao X, et al. Int J Biol Sci. 2024 Jan 1;20(2):784-800. doi: 10.7150/ijbs.82003. eCollection 2024. Int J Biol Sci. 2024. PMID: 38169643 Free PMC article. - Age-related hearing loss and its potential drug candidates: a systematic review.
Hu S, Sun Q, Xu F, Jiang N, Gao J. Hu S, et al. Chin Med. 2023 Sep 20;18(1):121. doi: 10.1186/s13020-023-00825-6. Chin Med. 2023. PMID: 37730634 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources